Companies /Healthcare

Biogen Inc

NASDAQ: BIIB Drug Manufacturers - General
$217.91
▼ $4.25 (−1.91%) today
Markets open · 11:49am ET

24/7 Wall St. View

Price Prediction $326.20 +46.4% Our analysts’ 12-month view: target, optimistic case, and floor. BIIB price prediction → Earnings Beat +73.6% EPS vs. the estimate, revenue, and how the market reacted. BIIB earnings history →

BIIB at a Glance

Valuation
Market cap
$32.8B
P/E ratio
39.5
Profitability
Revenue (TTM)
$10.0B
Profit margin
8.3%
EPS (TTM)
$5.63
Price
52-week range
$138 – $230
24/7 target
$326.20
Street target
$238.18
Earnings
Next report
Oct 28, 2026
Q2 2026 EPS
$3.60
vs. $2.07 est.
+73.6%

Headquartered in Cambridge, MA Fiscal year ends December NASDAQ: BIIB biogen.com

About Biogen

Biogen Inc. is a biotechnology company that discovers, develops, and delivers therapies for people living with serious neurological, rare, and autoimmune diseases. Its commercial portfolio spans multiple sclerosis (TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI), rare diseases (SPINRAZA for spinal muscular atrophy, SKYCLARYS for Friedreich's ataxia, QALSODY for ALS), Alzheimer's disease (LEQEMBI, in collaboration with Eisai), postpartum depression (ZURZUVAE), and following the 2026 acquisition of Apellis, specialized immunology and ophthalmology (SYFOVRE for geographic atrophy and EMPAVELI for PNH). Biogen also generates significant revenue from anti-CD20 therapeutic programs including royalties on OCREVUS and profit-sharing on RITUXAN, GAZYVA, and LUNSUMIO, as well as biosimilars marketed internationally (BENEPALI, IMRALDI, FLIXABI). The company is building a late-stage pipeline with programs in systemic and cutaneous lupus (litifilimab), antibody-mediated rejection (felzartamab), Dravet syndrome (zorevunersen), and Alzheimer's disease (diranersen, a tau-directed agent). Biogen trades on Nasdaq under the ticker BIIB. Updated

Latest Activity

House trade disclosureKevin Hern
  • ADBEAdobe Inc. - Common Stock (ADBE)Partial sell$15K – $50KAug 14
  • ALCHern Family Foundation Alcon Inc. Ordinary Shares (ALC)Sell$1K – $15KAug 5
  • BUDKevin Hern Traditional IRA Anheuser-Busch Inbev SA Sponsored ADR (BUD)Sell$1K – $15KAug 18
  • BIIBKevin Hern Traditional IRA Biogen Inc. - Common Stock (BIIB)Sell$1K – $15KAug 18
  • BABoeing Company (BA)Sell$1K – $15KAug 13
  • BABoeing Company (BA)Sell$15K – $50KAug 13
  • CANADIAN CNTY OKLA EDL FACS AUTH EDL 3.00000% 09/01/2029Buy$100K – $250KAug 24
  • CARRCarrier Global Corporation Common Stock (CARR)Sell$1K – $15KAug 14
+ 21 more trades in this filing
Made public 27 days after the earliest trade

Hern sold across 28 equity positions in August, from Adobe and Boeing to Microsoft and Home Depot, and put $100K to $250K into an Oklahoma municipal bond instead. That is a wholesale rotation out of stocks and into tax-free paper by a Ways and Means member now running for Senate, disclosed 27 days later.

Read more

BIIB Coverage

Load More

Frequently Asked Questions

What does Biogen do?

Biogen Inc. is a biotechnology company that discovers, develops, and delivers therapies for people living with serious neurological, rare, and autoimmune diseases.

What is the BIIB stock price target?

24/7 Wall St.'s 12-month price target for BIIB is $326.20, rated Buy. The Wall Street consensus target is $238.18. BIIB price prediction →